Tag Archives: Events

Successful Public-Private Partnerships

handshake

According to BayBio, biomedical companies that can harness the power of patient groups will get medicines, devices and diagnostics to market faster, cheaper and smarter, helping patients and rewarding investors. Gail Maderis, ‎President & CEO at BayBio, debuted their preliminary whitepaper entitled “Successful Public-Private Partnerships” today at the 2013 BIO Investor Forum. BayBio surveyed nearly 100 biotech and foundation CEOs, vice presidents of research, directors of patient advocacy and others across the United States. Following Read More >

Business and Investments  |  Leave a comment  |  Email This Post
Tags: , , , , ,

BIO Investor Forum Kicks Off Amid Industry Optimism

San Francisco skyline

Today, the BIO Investor Forum kicks off in San Francisco, Calif. BioWorld’s Catherine Shaffer paints a positive picture of the industry (subscription required) highlighting the strong IPO activity and heightened interest in the sector among investors. The conference reflects the upward momentum of the industry with increased expected attendance among both companies and investors. The JOBS Act is widely viewed as the underlying reason for these positive trends in the industry as the law helped Read More >

Business and Investments  |  Leave a comment  |  Email This Post
Tags: , , ,

BIO Investor Forum to Showcase NSF-funded Companies

150639480

No risk, no reward—that’s the concept driving the startups and entrepreneurs scheduled to present at next week’s 12th Annual BIO Investor Forum as a part of the newly-announced National Science Foundation (NSF) track of presenting companies. Expanding on the success of the Discovery Track Presentations, the 2013 BIO Investor Forum will feature a dedicated track of 10 NSF-funded companies focused on drug discovery, diagnostics and other related technologies. The companies are supported by the NSF Small Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , , , , , , ,

Prosensa’s IPO and the Value of the BIO Investor Forum

Hans Schikan

Prosensa (NASDAQ: RNA) is a Dutch biotechnology company engaged in the discovery and development of RNA-modulating therapeutics for the treatment of genetic disorders. Our primary focus is on rare neuromuscular and neurodegenerative disorders with a large unmet medical need, including Duchenne muscular dystrophy, myotonic dystrophy and Huntington’s disease. We completed an IPO onto NASDAQ in June of this year. Prior to last year’s BIO Investor Forum in San Francisco, we were still in the very Read More >

The One-on-One Compass  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , , ,

Call For Sessions – Speak Now. The Industry is Listening.

BIO_SESSIONS-homepage_115x76

BIO is seeking to bring the most innovative thinkers in biotechnology together at the BIO International Convention, June 23-26th, 2014, in San Diego, CA. Speaking at the BIO International Convention gives you access to biotech thought leaders from over 4,000 companies in 65 countries. BIO is seeking speakers who are forward leaning, engaging and who drive meaningful discussion about what’s on the forefront of the industry. Education enhancements in 2014 include: streamlined session tracks organized Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , , , ,